Fluence Selected by Compass Pathways to Develop Post-Approval COMP360 Provider Training

Fluence will build a COMP360-focused clinician certificate program to support potential U.S. use of Compass Pathways’ psilocybin treatment after FDA approval.

Rhea-AI Summary

Compass Pathways (CMPS) selected Fluence on September 10, 2026 to develop a post-approval U.S. healthcare provider training program for COMP360 psilocybin treatment, if the therapy receives FDA approval. The new Post-Approval COMP360 Psilocybin Certificate Program will prepare clinicians to support patients through the COMP360 treatment experience for treatment-resistant depression.

The curriculum will progress through three modules: Foundations of Psychedelic Care, Understanding Psilocybin, and COMP360 Certification. It will cover psychedelic care fundamentals, psilocybin science, and COMP360-specific topics including regulations, patient preparation, treatment administration, and follow-up. Fluence was chosen via a competitive process based on its psychedelic training expertise, scalability, and regulatory alignment.

Market Context

CMPS had already gained 8.05% before this headline, while a comparable provider-education update on ...

Analysis

CMPS had already gained 8.05% before this headline, while a comparable provider-education update on Sep 08 was followed by a 5.8% 24-hour reaction. Those observations contextualized the collaboration but were not reactions to this announcement.

Historical Context

2 past events · Latest: Sep 09

2 events

1. Sep 09

   Phase 3 data

   24h Move

   +8.1%

   52-week COMP005 data showed durable benefit and ongoing NDA submission

2. Sep 08

   HCP education campaign

   24h Move

   +5.8%

   Compass announced U.S. provider education campaign and new HEOR presentations

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Key Terms

psilocybin, treatment-resistant depression, fda

3 terms

psilocybin medical

"patients receiving COMP360 psilocybin treatment"

A naturally occurring psychedelic compound found in certain mushrooms that alters perception, mood and consciousness; when taken the body converts it into an active substance that produces short-term hallucinogenic effects. Investors watch psilocybin because researchers and drug developers are exploring it as a potential treatment for depression, PTSD and other mental health conditions, so clinical trial results, regulatory decisions and changing stigma can create large commercial opportunities or risks—think of it as a new drug category whose approval pathway can drive big swings in company value.

treatment-resistant depression medical

"evaluated for treatment-resistant depression"

A form of major depression that does not improve after a person has tried standard treatments such as common antidepressant medications and therapy; think of it as a stubborn problem that doesn’t respond to the usual fixes. It matters to investors because it represents a large unmet medical need and a higher-risk, higher-reward area for drug developers, with potential for premium pricing, regulatory scrutiny, and durable demand if an effective new therapy is approved.

fda regulatory

"if approved by the U.S. Food and Drug Administration (FDA)"

The FDA is the U.S. federal agency that evaluates and approves medical drugs, devices, biological therapies and certain foods; think of it as the gatekeeper that decides whether a medical product is safe and effective for patients. For investors, FDA decisions determine whether a company can sell a product, affect expected revenue and introduce regulatory risk, so approvals, rejections or safety warnings can quickly move a company's valuation and stock price.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

New certificate program will prepare clinicians to support patients receiving COMP360 psilocybin treatment, if approved by the FDA

NEW YORK, Sept. 10, 2026 /PRNewswire/ -- Fluence, a leading provider of professional education in psychedelic therapy, today announced that it has been selected by Compass Pathways plc (Nasdaq: CMPS) as a recipient of its U.S. healthcare provider training grant program. Through the collaboration, Fluence is developing a new certificate program designed to prepare healthcare providers to deliver high-quality care for patients receiving COMP360 psilocybin treatment, if approved by the U.S. Food and Drug Administration (FDA).

COMP360 is an investigational synthetic psilocybin treatment currently being evaluated for treatment-resistant depression. In anticipation of potential FDA approval and subsequent commercial availability, the Post-Approval COMP360 Psilocybin Certificate Program will prepare clinicians with the knowledge and skills required to support patients throughout the COMP360 treatment experience. The program will combine Fluence's experience training thousands of clinicians in psychedelic therapy with Compass Pathways' clinical guidance for COMP360.

The certificate program will progress through three modules: Foundations of Psychedelic Care, Understanding Psilocybin, and COMP360 Certification. Clinicians will build foundational skills for supporting patients through psychedelic treatment, develop an understanding of psilocybin and the research behind its therapeutic use, and receive COMP360-specific training covering the compound, applicable regulations, patient preparation, treatment administration, and follow-up.

"This is a moment Fluence has been preparing for since our earliest days," said Elizabeth Nielson, PhD, Chief Executive Officer and Co-Founder of Fluence. "Our goal has always been to help clinicians translate rigorous psychedelic research into safe, skilled and evidence-based clinical practice. Working with Compass to prepare providers for the potential introduction of COMP360 allows us to bring together years of clinician education and clinical research training in a program designed for real-world care."

Fluence was a training partner selected by Compass Pathways through a competitive process based on expertise in psychedelic training design, delivery and governance, ability to scale, commitment to access and inclusion, and regulatory alignment.

In addition to training individual clinicians, Fluence supports healthcare organizations preparing and managing clinical workforces at scale. Through its training operations platform, organizations can enroll providers and access real-time data on training progress, completion, competency and credentialing, providing the visibility and documentation needed to develop a consistently trained and verifiably prepared workforce.

To pre-enroll or learn more visit our website.

About Fluence

Fluence builds the human capabilities required for psychedelic and neuroplastogen care. Through evidence-based training, expert instruction, experiential practice and competency assessment, Fluence prepares clinicians to deliver high-quality care and enables organizations to develop competent, consistently trained and verifiably prepared providers. Fluence's programs are grounded in clinical research and designed for the realities and responsibilities of clinical practice. www.fluencetraining.com 

View original content to download multimedia:https://www.prnewswire.com/news-releases/fluence-selected-by-compass-pathways-to-develop-post-approval-comp360-provider-training-302875218.html

SOURCE Fluence International, Inc.

FAQ

What is COMP360 and what condition is it being developed for?

COMP360 is an investigational synthetic psilocybin treatment that is being evaluated for the treatment of treatment-resistant depression. The clinician training program described will apply only if COMP360 is approved by the U.S. Food and Drug Administration.

What topics will the Post-Approval COMP360 Psilocybin Certificate Program cover?

The program has three modules: Foundations of Psychedelic Care, Understanding Psilocybin, and COMP360 Certification. It will build foundational skills for supporting patients through psychedelic treatment, explain psilocybin and research behind its therapeutic use, and provide COMP360-specific training on the compound, applicable regulations, patient preparation, treatment administration, and follow-up.

Why was Fluence chosen as a training partner for COMP360?

Fluence was selected through a competitive process based on its expertise in psychedelic training design, delivery and governance, its ability to scale training, its commitment to access and inclusion, and its alignment with regulatory expectations.

Does Fluence also support healthcare organizations, not just individual clinicians?

Fluence supports both. It trains individual clinicians and also works with healthcare organizations through a training operations platform that allows organizations to enroll providers and monitor real-time data on training progress, completion, competency and credentialing, to build a consistently trained workforce.

How can clinicians pre-enroll or get more information about the COMP360 training?

Clinicians can pre-enroll or learn more about the Post-Approval COMP360 Psilocybin Certificate Program by visiting Fluence’s website, as directed in the announcement.